Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
Tumor Center - Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany.
Oral Oncol. 2020 Dec;111:105009. doi: 10.1016/j.oraloncology.2020.105009. Epub 2020 Oct 6.
Numerous studies analyzed lymphovascular invasion (LVI) in various malignant diseases, however, little is known about the role of lymphatic invasion (LI) as well as vascular invasion (VI) in oral squamous cell carcinoma (OSCC). The aim of this study is to illuminate the role of LI and VI in a population-based cohort study.
We retrospectively analyzed 745 primarily resected OSCC patients in Eastern Bavaria for histopathologically verified LI and VI. Overall survival (OS) and recurrence-free survival (RFS) were calculated, whereas analysis was performed by uni- and multivariate statistics. Mean follow-up time was 7.4 years.
LI was found in 115 patients (15.4%), VI was diagnosed in 23 cases (3.1%). LI correlated significantly with distinct anatomical sites (p = 0.004), increasing pT-classification (p < 0.001), lymph node involvement (p < 0.001), higher grading (p < 0.001), advanced UICC-stages (p < 0.001) and adjuvant therapies (p < 0.001). Similar results were found for VI. Survival analysis resulted in a significantly decreased five-year OS and RFS in patients with diagnosed LI (OS: 41.1%, RFS: 38.3%) in contrast to LI-negative cases (OS: 66.8%, RFS: 59.7.7%, p < 0.001). Analogous outcomes were seen for patients with VI. Additionally, LI was identified as a predictive parameter, indicating individual patients' response to adjuvant therapies.
This population-based cohort study underlines the unfavorable aspect of LI and VI on outcome in OSCC. Including LI and VI in existing staging systems could help to stratify patients' risk for adverse outcome and consecutively determine adjuvant treatment in malignant disease.
许多研究分析了各种恶性疾病中的淋巴血管侵犯(LVI),然而,对于淋巴管侵犯(LI)和血管侵犯(VI)在口腔鳞状细胞癌(OSCC)中的作用知之甚少。本研究的目的是在基于人群的队列研究中阐明 LI 和 VI 的作用。
我们回顾性分析了东巴伐利亚地区 745 例经组织病理学证实的原发性 OSCC 患者的 LI 和 VI。计算总生存期(OS)和无复发生存期(RFS),并通过单因素和多因素统计进行分析。平均随访时间为 7.4 年。
115 例(15.4%)患者存在 LI,23 例(3.1%)患者存在 VI。LI 与明显的解剖部位显著相关(p=0.004),增加 pT 分期(p<0.001)、淋巴结受累(p<0.001)、更高的分级(p<0.001)、晚期 UICC 分期(p<0.001)和辅助治疗(p<0.001)。VI 也有类似的结果。生存分析显示,LI 阳性患者的五年 OS 和 RFS 明显降低(OS:41.1%,RFS:38.3%),而 LI 阴性患者的 OS 和 RFS 分别为(OS:66.8%,RFS:59.7%,p<0.001)。VI 阳性患者也出现了类似的结果。此外,LI 被确定为一个预测参数,表明个体患者对辅助治疗的反应。
本基于人群的队列研究强调了 LI 和 VI 对 OSCC 结局的不利影响。将 LI 和 VI 纳入现有的分期系统可以帮助分层患者不良预后的风险,并继而确定恶性疾病的辅助治疗。